相关实验视频

Updated: Jan 11, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

由等离子体转化Bifidobacterium longum 105A分泌β-葡萄糖酶,用于SN-38葡萄糖化物的前药物转化

Atsushi Saisho¹, Michiko Shimokawa², Rintaro Kubo¹

¹Advanced Cancer Medicine for Gynecologic Cancer, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan; Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.

Protein expression and purification

|November 12, 2025

概括

研究人员设计了一种Bifidobacterium longum菌株,专门在瘤内激活癌症前药SN-38葡萄化物 (SN-38G). 这种微生物方法增强了向药物输送,并减少了副作用,从而改善了癌症药物治疗.

科学领域:

生物技术是生物技术.
癌症药理疗癌症药理疗
微生物工程微生物工程

背景情况:

瘤选择性前药激活对于有效的癌症治疗至关重要.
SN-38葡萄胺 (SN-38G) 是一种水友性前药物,需要由β-葡萄胺酶进行水解来激活.
低膜透性限制了SN-38G的有效性.

研究的目的:

为在瘤内进行局部SN-38G激活的Bifidobacterium longum 105A菌株进行工程.
为了证明微生物增强的前药激活策略的可行性.

主要方法:

设计了一种重组Bifidobacterium longum 105A以分泌β-葡萄糖酶.
在模拟瘤微环境条件下评估酶活性 (无氧,酸性,缺氧).
在CT26结肠癌细胞中使用MTT试验和HPLC评估了SN-38G转化和细胞毒性.

主要成果:

分泌的β-glucuronidase在类似瘤的条件下保持稳定的活性.
与工程细菌和SN-38G的同时治疗显著抑制了CT26细胞生长.
在HPLC中证实了SN-38G转化为活性SN-38代谢物.

结论:

使用Bifidobacterium longum进行微生物增强的前药激活的概念验证.
由等离子体驱动的表达使SN-38的向释放和激活成为可能.
开发各种抗癌前期药物的瘤局部化药物生产系统的潜力.

关键词:

这种细菌是Bifidobacterium.药物输送和制造系统是药物输送和制造系统.一个药物产品.SN-38 标签: 美国这是一种β-glucuronidase.

更多相关视频

FIBS-enabled Noninvasive Metabolic Profiling

FIBS-enabled Noninvasive Metabolic Profiling

Published on: February 3, 2014

Bacterial Peptide Display for the Selection of Novel Biotinylating Enzymes

Bacterial Peptide Display for the Selection of Novel Biotinylating Enzymes

Published on: October 3, 2019

相关概念视频

Drug Biotransformation: Overview

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...

Drug Metabolism: Phase II Reactions

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...

Phase II Reactions: Glucuronidation

Phase II Reactions: Glucuronidation

Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...